Serveur d'exploration sur l'opéra

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The ω-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation trial--rationale and design.

Identifieur interne : 000311 ( PubMed/Curation ); précédent : 000310; suivant : 000312

The ω-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation trial--rationale and design.

Auteurs : Dariush Mozaffarian [États-Unis] ; Roberto Marchioli ; Tim Gardner ; Paolo Ferrazzi ; Patrick O'Gara ; Roberto Latini ; Peter Libby ; Federico Lombardi ; Alejandro Macchia ; Richard Page ; Massimo Santini ; Luigi Tavazzi ; Gianni Tognoni

Source :

RBID : pubmed:21742090

English descriptors

Abstract

Postoperative atrial fibrillation/flutter (PoAF) commonly complicates cardiac surgery, occurring in 25% to 60% of patients. Postoperative atrial fibrillation/flutter is associated with significant morbidity, higher long-term mortality, and increased health care costs. Novel preventive therapies are clearly needed. In experiments and short-term trials, seafood-derived long-chain ω-3 polyunsaturated fatty acids (PUFAs) influence several risk factors that might reduce risk of PoAF. A few small and generally underpowered trials have evaluated effects of ω-3-PUFAs supplementation on PoAF with mixed results. The OPERA trial is an appropriately powered, investigator-initiated, randomized, double-blind, placebo-controlled, multinational trial to determine whether perioperative oral ω-3-PUFAs reduces occurrence of PoAF in patients undergoing cardiac surgery. Additional aims include evaluation of resource use, biologic pathways and mechanisms, postoperative cognitive decline, and safety. Broad inclusion criteria encompass a "real-world" population of outpatients and inpatients scheduled for cardiac surgery. Treatment comprises a total preoperative loading dose of 8 to 10 g of ω-3-PUFAs or placebo divided over 2 to 5 days, followed by 2 g/d until hospital discharge or postoperative day 10, whichever comes first. Based on anticipated 30% event rate in controls, total enrollment of 1,516 patients (758 per treatment arm) will provide 90% power to detect 25% reduction in PoAF. The OPERA trial will provide invaluable evidence to inform biologic pathways; proof of concept that ω-3-PUFAs influence cardiac arrhythmias; and potential regulatory standards and clinical use of this simple, inexpensive, and low-risk intervention to prevent PoAF.

DOI: 10.1016/j.ahj.2011.03.035
PubMed: 21742090

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:21742090

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The ω-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation trial--rationale and design.</title>
<author>
<name sortKey="Mozaffarian, Dariush" sort="Mozaffarian, Dariush" uniqKey="Mozaffarian D" first="Dariush" last="Mozaffarian">Dariush Mozaffarian</name>
<affiliation wicri:level="1">
<nlm:affiliation>Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. dmozaffa@hsph.harvard.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Marchioli, Roberto" sort="Marchioli, Roberto" uniqKey="Marchioli R" first="Roberto" last="Marchioli">Roberto Marchioli</name>
</author>
<author>
<name sortKey="Gardner, Tim" sort="Gardner, Tim" uniqKey="Gardner T" first="Tim" last="Gardner">Tim Gardner</name>
</author>
<author>
<name sortKey="Ferrazzi, Paolo" sort="Ferrazzi, Paolo" uniqKey="Ferrazzi P" first="Paolo" last="Ferrazzi">Paolo Ferrazzi</name>
</author>
<author>
<name sortKey="O Gara, Patrick" sort="O Gara, Patrick" uniqKey="O Gara P" first="Patrick" last="O'Gara">Patrick O'Gara</name>
</author>
<author>
<name sortKey="Latini, Roberto" sort="Latini, Roberto" uniqKey="Latini R" first="Roberto" last="Latini">Roberto Latini</name>
</author>
<author>
<name sortKey="Libby, Peter" sort="Libby, Peter" uniqKey="Libby P" first="Peter" last="Libby">Peter Libby</name>
</author>
<author>
<name sortKey="Lombardi, Federico" sort="Lombardi, Federico" uniqKey="Lombardi F" first="Federico" last="Lombardi">Federico Lombardi</name>
</author>
<author>
<name sortKey="Macchia, Alejandro" sort="Macchia, Alejandro" uniqKey="Macchia A" first="Alejandro" last="Macchia">Alejandro Macchia</name>
</author>
<author>
<name sortKey="Page, Richard" sort="Page, Richard" uniqKey="Page R" first="Richard" last="Page">Richard Page</name>
</author>
<author>
<name sortKey="Santini, Massimo" sort="Santini, Massimo" uniqKey="Santini M" first="Massimo" last="Santini">Massimo Santini</name>
</author>
<author>
<name sortKey="Tavazzi, Luigi" sort="Tavazzi, Luigi" uniqKey="Tavazzi L" first="Luigi" last="Tavazzi">Luigi Tavazzi</name>
</author>
<author>
<name sortKey="Tognoni, Gianni" sort="Tognoni, Gianni" uniqKey="Tognoni G" first="Gianni" last="Tognoni">Gianni Tognoni</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="doi">10.1016/j.ahj.2011.03.035</idno>
<idno type="RBID">pubmed:21742090</idno>
<idno type="pmid">21742090</idno>
<idno type="wicri:Area/PubMed/Corpus">000311</idno>
<idno type="wicri:Area/PubMed/Curation">000311</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">The ω-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation trial--rationale and design.</title>
<author>
<name sortKey="Mozaffarian, Dariush" sort="Mozaffarian, Dariush" uniqKey="Mozaffarian D" first="Dariush" last="Mozaffarian">Dariush Mozaffarian</name>
<affiliation wicri:level="1">
<nlm:affiliation>Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. dmozaffa@hsph.harvard.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Marchioli, Roberto" sort="Marchioli, Roberto" uniqKey="Marchioli R" first="Roberto" last="Marchioli">Roberto Marchioli</name>
</author>
<author>
<name sortKey="Gardner, Tim" sort="Gardner, Tim" uniqKey="Gardner T" first="Tim" last="Gardner">Tim Gardner</name>
</author>
<author>
<name sortKey="Ferrazzi, Paolo" sort="Ferrazzi, Paolo" uniqKey="Ferrazzi P" first="Paolo" last="Ferrazzi">Paolo Ferrazzi</name>
</author>
<author>
<name sortKey="O Gara, Patrick" sort="O Gara, Patrick" uniqKey="O Gara P" first="Patrick" last="O'Gara">Patrick O'Gara</name>
</author>
<author>
<name sortKey="Latini, Roberto" sort="Latini, Roberto" uniqKey="Latini R" first="Roberto" last="Latini">Roberto Latini</name>
</author>
<author>
<name sortKey="Libby, Peter" sort="Libby, Peter" uniqKey="Libby P" first="Peter" last="Libby">Peter Libby</name>
</author>
<author>
<name sortKey="Lombardi, Federico" sort="Lombardi, Federico" uniqKey="Lombardi F" first="Federico" last="Lombardi">Federico Lombardi</name>
</author>
<author>
<name sortKey="Macchia, Alejandro" sort="Macchia, Alejandro" uniqKey="Macchia A" first="Alejandro" last="Macchia">Alejandro Macchia</name>
</author>
<author>
<name sortKey="Page, Richard" sort="Page, Richard" uniqKey="Page R" first="Richard" last="Page">Richard Page</name>
</author>
<author>
<name sortKey="Santini, Massimo" sort="Santini, Massimo" uniqKey="Santini M" first="Massimo" last="Santini">Massimo Santini</name>
</author>
<author>
<name sortKey="Tavazzi, Luigi" sort="Tavazzi, Luigi" uniqKey="Tavazzi L" first="Luigi" last="Tavazzi">Luigi Tavazzi</name>
</author>
<author>
<name sortKey="Tognoni, Gianni" sort="Tognoni, Gianni" uniqKey="Tognoni G" first="Gianni" last="Tognoni">Gianni Tognoni</name>
</author>
</analytic>
<series>
<title level="j">American heart journal</title>
<idno type="e-ISSN">1097-6744</idno>
<imprint>
<date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Administration, Oral</term>
<term>Adolescent</term>
<term>Atrial Fibrillation (etiology)</term>
<term>Atrial Fibrillation (physiopathology)</term>
<term>Atrial Fibrillation (prevention & control)</term>
<term>Cardiac Surgical Procedures (adverse effects)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Fatty Acids, Omega-3 (administration & dosage)</term>
<term>Follow-Up Studies</term>
<term>Heart Diseases (surgery)</term>
<term>Humans</term>
<term>Postoperative Complications</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Fatty Acids, Omega-3</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en">
<term>Cardiac Surgical Procedures</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Atrial Fibrillation</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Atrial Fibrillation</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Atrial Fibrillation</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en">
<term>Heart Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Administration, Oral</term>
<term>Adolescent</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Postoperative Complications</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Postoperative atrial fibrillation/flutter (PoAF) commonly complicates cardiac surgery, occurring in 25% to 60% of patients. Postoperative atrial fibrillation/flutter is associated with significant morbidity, higher long-term mortality, and increased health care costs. Novel preventive therapies are clearly needed. In experiments and short-term trials, seafood-derived long-chain ω-3 polyunsaturated fatty acids (PUFAs) influence several risk factors that might reduce risk of PoAF. A few small and generally underpowered trials have evaluated effects of ω-3-PUFAs supplementation on PoAF with mixed results. The OPERA trial is an appropriately powered, investigator-initiated, randomized, double-blind, placebo-controlled, multinational trial to determine whether perioperative oral ω-3-PUFAs reduces occurrence of PoAF in patients undergoing cardiac surgery. Additional aims include evaluation of resource use, biologic pathways and mechanisms, postoperative cognitive decline, and safety. Broad inclusion criteria encompass a "real-world" population of outpatients and inpatients scheduled for cardiac surgery. Treatment comprises a total preoperative loading dose of 8 to 10 g of ω-3-PUFAs or placebo divided over 2 to 5 days, followed by 2 g/d until hospital discharge or postoperative day 10, whichever comes first. Based on anticipated 30% event rate in controls, total enrollment of 1,516 patients (758 per treatment arm) will provide 90% power to detect 25% reduction in PoAF. The OPERA trial will provide invaluable evidence to inform biologic pathways; proof of concept that ω-3-PUFAs influence cardiac arrhythmias; and potential regulatory standards and clinical use of this simple, inexpensive, and low-risk intervention to prevent PoAF.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">21742090</PMID>
<DateCreated>
<Year>2011</Year>
<Month>07</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2011</Year>
<Month>09</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised>
<Year>2015</Year>
<Month>02</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-6744</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>162</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2011</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>American heart journal</Title>
<ISOAbbreviation>Am. Heart J.</ISOAbbreviation>
</Journal>
<ArticleTitle>The ω-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation trial--rationale and design.</ArticleTitle>
<Pagination>
<MedlinePgn>56-63.e3</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ahj.2011.03.035</ELocationID>
<Abstract>
<AbstractText>Postoperative atrial fibrillation/flutter (PoAF) commonly complicates cardiac surgery, occurring in 25% to 60% of patients. Postoperative atrial fibrillation/flutter is associated with significant morbidity, higher long-term mortality, and increased health care costs. Novel preventive therapies are clearly needed. In experiments and short-term trials, seafood-derived long-chain ω-3 polyunsaturated fatty acids (PUFAs) influence several risk factors that might reduce risk of PoAF. A few small and generally underpowered trials have evaluated effects of ω-3-PUFAs supplementation on PoAF with mixed results. The OPERA trial is an appropriately powered, investigator-initiated, randomized, double-blind, placebo-controlled, multinational trial to determine whether perioperative oral ω-3-PUFAs reduces occurrence of PoAF in patients undergoing cardiac surgery. Additional aims include evaluation of resource use, biologic pathways and mechanisms, postoperative cognitive decline, and safety. Broad inclusion criteria encompass a "real-world" population of outpatients and inpatients scheduled for cardiac surgery. Treatment comprises a total preoperative loading dose of 8 to 10 g of ω-3-PUFAs or placebo divided over 2 to 5 days, followed by 2 g/d until hospital discharge or postoperative day 10, whichever comes first. Based on anticipated 30% event rate in controls, total enrollment of 1,516 patients (758 per treatment arm) will provide 90% power to detect 25% reduction in PoAF. The OPERA trial will provide invaluable evidence to inform biologic pathways; proof of concept that ω-3-PUFAs influence cardiac arrhythmias; and potential regulatory standards and clinical use of this simple, inexpensive, and low-risk intervention to prevent PoAF.</AbstractText>
<CopyrightInformation>Copyright © 2011 Mosby, Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mozaffarian</LastName>
<ForeName>Dariush</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. dmozaffa@hsph.harvard.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marchioli</LastName>
<ForeName>Roberto</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gardner</LastName>
<ForeName>Tim</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ferrazzi</LastName>
<ForeName>Paolo</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>O'Gara</LastName>
<ForeName>Patrick</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Latini</LastName>
<ForeName>Roberto</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Libby</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lombardi</LastName>
<ForeName>Federico</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Macchia</LastName>
<ForeName>Alejandro</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Page</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Santini</LastName>
<ForeName>Massimo</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tavazzi</LastName>
<ForeName>Luigi</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tognoni</LastName>
<ForeName>Gianni</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList>
<AccessionNumber>NCT00970489</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>RC2 HL101816</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>RC2 HL101816-01</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>RC2-HL101816</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D057666">Research Support, American Recovery and Reinvestment Act</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2011</Year>
<Month>06</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am Heart J</MedlineTA>
<NlmUniqueID>0370465</NlmUniqueID>
<ISSNLinking>0002-8703</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Circulation. 2000 Mar 28;101(12):1403-8</RefSource>
<PMID Version="1">10736284</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Am Coll Cardiol. 2011 Nov 8;58(20):2047-67</RefSource>
<PMID Version="1">22051327</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet. 2003 Feb 8;361(9356):477-85</RefSource>
<PMID Version="1">12583947</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>JAMA. 2004 Apr 14;291(14):1720-9</RefSource>
<PMID Version="1">15082699</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Circulation. 2004 Jul 27;110(4):368-73</RefSource>
<PMID Version="1">15262826</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet. 1989 Jul 22;2(8656):177-81</RefSource>
<PMID Version="1">2568519</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arterioscler Thromb. 1991 Jul-Aug;11(4):903-11</RefSource>
<PMID Version="1">1829632</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood Coagul Fibrinolysis. 1995 Feb;6(1):17-22</RefSource>
<PMID Version="1">7795149</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>JAMA. 1996 Jul 24-31;276(4):300-6</RefSource>
<PMID Version="1">8656542</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Am Coll Cardiol. 2005 May 17;45(10):1723-8</RefSource>
<PMID Version="1">15893193</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cardiovasc Surg (Torino). 2005 Dec;46(6):583-8</RefSource>
<PMID Version="1">16424847</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur Heart J. 2006 Dec;27(23):2846-57</RefSource>
<PMID Version="1">17015402</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Circulation. 2008 Oct 14;118(16):1612-8</RefSource>
<PMID Version="1">18824644</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Clin Pharmacol. 2008 Jun;64(6):627-34</RefSource>
<PMID Version="1">18309477</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Thorac Cardiovasc Surg. 2009 Aug;57(5):276-80</RefSource>
<PMID Version="1">19629889</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Circulation. 2009 Dec 8;120(23):2315-21</RefSource>
<PMID Version="1">19933935</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Circ Cardiovasc Qual Outcomes. 2009 May;2(3):164-9</RefSource>
<PMID Version="1">20031833</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Circ Arrhythm Electrophysiol. 2010 Feb;3(1):46-53</RefSource>
<PMID Version="1">20042769</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Am Coll Cardiol. 2010 Mar 30;55(13):1370-6</RefSource>
<PMID Version="1">20338499</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur Heart J. 2010 Oct;31(19):2369-429</RefSource>
<PMID Version="1">20802247</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>JAMA. 2010 Dec 1;304(21):2363-72</RefSource>
<PMID Version="1">21078810</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Crit Care. 2002 May;11(3):228-38</RefSource>
<PMID Version="1">12022486</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001281">Atrial Fibrillation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006348">Cardiac Surgical Procedures</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015525">Fatty Acids, Omega-3</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006331">Heart Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011183">Postoperative Complications</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS304087</OtherID>
<OtherID Source="NLM">PMC3134828</OtherID>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2011</Year>
<Month>2</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2011</Year>
<Month>3</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="aheadofprint">
<Year>2011</Year>
<Month>6</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2011</Year>
<Month>7</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2011</Year>
<Month>7</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2011</Year>
<Month>9</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pii">S0002-8703(11)00265-1</ArticleId>
<ArticleId IdType="doi">10.1016/j.ahj.2011.03.035</ArticleId>
<ArticleId IdType="pubmed">21742090</ArticleId>
<ArticleId IdType="pmc">PMC3134828</ArticleId>
<ArticleId IdType="mid">NIHMS304087</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000311 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000311 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:21742090
   |texte=   The ω-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation trial--rationale and design.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:21742090" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a OperaV1 

Wicri

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Oct 8 06:48:41 2020